S&P 500   5,091.14 (+0.05%)
DOW   39,217.47 (+0.22%)
QQQ   437.92 (+0.26%)
AAPL   181.57 (-0.52%)
MSFT   410.63 (+0.07%)
META   483.97 (-0.01%)
GOOGL   141.07 (-2.01%)
AMZN   175.44 (+0.26%)
TSLA   195.55 (+1.86%)
NVDA   798.08 (+1.26%)
NIO   5.63 (+4.26%)
AMD   177.84 (+0.75%)
BABA   76.14 (+0.24%)
T   16.75 (-0.30%)
F   12.15 (+0.08%)
MU   91.48 (+6.37%)
CGC   3.42 (+1.79%)
GE   154.30 (+0.63%)
DIS   108.15 (+0.38%)
AMC   4.51 (+1.58%)
PFE   27.37 (-1.40%)
PYPL   58.91 (-0.42%)
XOM   103.59 (-0.24%)
S&P 500   5,091.14 (+0.05%)
DOW   39,217.47 (+0.22%)
QQQ   437.92 (+0.26%)
AAPL   181.57 (-0.52%)
MSFT   410.63 (+0.07%)
META   483.97 (-0.01%)
GOOGL   141.07 (-2.01%)
AMZN   175.44 (+0.26%)
TSLA   195.55 (+1.86%)
NVDA   798.08 (+1.26%)
NIO   5.63 (+4.26%)
AMD   177.84 (+0.75%)
BABA   76.14 (+0.24%)
T   16.75 (-0.30%)
F   12.15 (+0.08%)
MU   91.48 (+6.37%)
CGC   3.42 (+1.79%)
GE   154.30 (+0.63%)
DIS   108.15 (+0.38%)
AMC   4.51 (+1.58%)
PFE   27.37 (-1.40%)
PYPL   58.91 (-0.42%)
XOM   103.59 (-0.24%)
S&P 500   5,091.14 (+0.05%)
DOW   39,217.47 (+0.22%)
QQQ   437.92 (+0.26%)
AAPL   181.57 (-0.52%)
MSFT   410.63 (+0.07%)
META   483.97 (-0.01%)
GOOGL   141.07 (-2.01%)
AMZN   175.44 (+0.26%)
TSLA   195.55 (+1.86%)
NVDA   798.08 (+1.26%)
NIO   5.63 (+4.26%)
AMD   177.84 (+0.75%)
BABA   76.14 (+0.24%)
T   16.75 (-0.30%)
F   12.15 (+0.08%)
MU   91.48 (+6.37%)
CGC   3.42 (+1.79%)
GE   154.30 (+0.63%)
DIS   108.15 (+0.38%)
AMC   4.51 (+1.58%)
PFE   27.37 (-1.40%)
PYPL   58.91 (-0.42%)
XOM   103.59 (-0.24%)
S&P 500   5,091.14 (+0.05%)
DOW   39,217.47 (+0.22%)
QQQ   437.92 (+0.26%)
AAPL   181.57 (-0.52%)
MSFT   410.63 (+0.07%)
META   483.97 (-0.01%)
GOOGL   141.07 (-2.01%)
AMZN   175.44 (+0.26%)
TSLA   195.55 (+1.86%)
NVDA   798.08 (+1.26%)
NIO   5.63 (+4.26%)
AMD   177.84 (+0.75%)
BABA   76.14 (+0.24%)
T   16.75 (-0.30%)
F   12.15 (+0.08%)
MU   91.48 (+6.37%)
CGC   3.42 (+1.79%)
GE   154.30 (+0.63%)
DIS   108.15 (+0.38%)
AMC   4.51 (+1.58%)
PFE   27.37 (-1.40%)
PYPL   58.91 (-0.42%)
XOM   103.59 (-0.24%)

IDEAYA Biosciences (IDYA) Stock Price, News & Analysis

$46.40
+0.52 (+1.13%)
(As of 09:38 AM ET)
Today's Range
$45.52
$46.65
50-Day Range
$33.55
$47.13
52-Week Range
$13.29
$47.74
Volume
12,961 shs
Average Volume
1.02 million shs
Market Capitalization
$3.46 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$39.09

IDEAYA Biosciences MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
15.8% Downside
$39.09 Price Target
Short Interest
Bearish
12.37% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.99
Upright™ Environmental Score
News Sentiment
0.35mentions of IDEAYA Biosciences in the last 14 days
Based on 43 Articles This Week
Insider Trading
Selling Shares
$7.03 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.24) to ($2.64) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.40 out of 5 stars

Medical Sector

514th out of 935 stocks

Pharmaceutical Preparations Industry

235th out of 429 stocks


IDYA stock logo

About IDEAYA Biosciences Stock (NASDAQ:IDYA)

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase II clinical trial for patients with solid tumors having methylthioadenosine phosphorylase gene deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester todevelop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase II/III study in metastatic uveal melanoma, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

IDYA Stock Price History

IDYA Stock News Headlines

Blue Chips And Billionaires Quietly Investing In "The New Oil"
They're as essential to the tech and AI revolutions as oil was to the industrial revolution. Known as rare earth elements or REEs, these relatively unheard of commodities are essential to semiconductor chips, renewable energy, electric vehicles, and more.
Blue Chips And Billionaires Quietly Investing In "The New Oil"
They're as essential to the tech and AI revolutions as oil was to the industrial revolution. Known as rare earth elements or REEs, these relatively unheard of commodities are essential to semiconductor chips, renewable energy, electric vehicles, and more.
The Analyst Verdict: IDEAYA Biosciences In The Eyes Of 6 Experts
Recap: IDEAYA Biosciences Q4 Earnings
IDEAYA Biosciences Q4 Results Misses Estimates
Ideaya Biosciences: A Strong Bet In Targeted Oncology
IDYA Apr 2024 35.000 put
IDYA Apr 2024 45.000 put
IDYA Mar 2024 35.000 put
IDEAYA Biosciences Inc CEO Yujiro Hata Sells 99,372 Shares
IDYA Apr 2024 50.000 put
See More Headlines
Receive IDYA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEAYA Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/20/2024
Today
2/25/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:IDYA
Fax
N/A
Employees
122
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$39.09
High Stock Price Target
$57.00
Low Stock Price Target
$24.00
Potential Upside/Downside
-14.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
12 Analysts

Profitability

Net Income
$-58,650,000.00
Net Margins
-483.05%
Pretax Margin
-483.05%

Debt

Sales & Book Value

Annual Sales
$23.39 million
Book Value
$8.33 per share

Miscellaneous

Free Float
70,757,000
Market Cap
$3.42 billion
Optionable
Optionable
Beta
0.83
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. Yujiro S. HataMr. Yujiro S. Hata (Age 50)
    Co-Founder, President, CEO & Director
    Comp: $851.7k
  • Dr. Michael A. White Ph.D. (Age 58)
    Chief Scientific Officer
    Comp: $613.85k
  • Dr. Darrin M. Beaupre M.D. (Age 57)
    Ph.D., Chief Medical Officer
    Comp: $152.64k
  • Dr. Jeffrey Hager Ph.D. (Age 59)
    Co -Founder
  • Mr. Andres Ruiz Briseno CPA (Age 38)
    Principal Accounting Officer, Senior VP and Head of Finance & Investor Relations
  • Dr. Paul A. Barsanti Ph.D.
    Chief Technology Officer
  • Mr. Jason S. Throne Esq. (Age 52)
    J.D., Chief Legal Officer & Company Secretary
    Comp: $425.56k
  • Mr. Mick O'Quigley
    Chief of Staff & Clinical Development














IDYA Stock Analysis - Frequently Asked Questions

Should I buy or sell IDEAYA Biosciences stock right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IDEAYA Biosciences in the last year. There are currently 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IDYA shares.
View IDYA analyst ratings
or view top-rated stocks.

What is IDEAYA Biosciences' stock price target for 2024?

12 analysts have issued 1 year price targets for IDEAYA Biosciences' stock. Their IDYA share price targets range from $24.00 to $57.00. On average, they predict the company's share price to reach $39.09 in the next year. This suggests that the stock has a possible downside of 15.8%.
View analysts price targets for IDYA
or view top-rated stocks among Wall Street analysts.

How have IDYA shares performed in 2024?

IDEAYA Biosciences' stock was trading at $35.58 at the start of the year. Since then, IDYA shares have increased by 30.4% and is now trading at $46.40.
View the best growth stocks for 2024 here
.

When is IDEAYA Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our IDYA earnings forecast
.

How were IDEAYA Biosciences' earnings last quarter?

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) issued its earnings results on Tuesday, February, 20th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.47) by $0.05. The firm earned $3.90 million during the quarter, compared to the consensus estimate of $8.84 million. IDEAYA Biosciences had a negative net margin of 483.05% and a negative trailing twelve-month return on equity of 23.00%. IDEAYA Biosciences's quarterly revenue was down 3.0% compared to the same quarter last year.

What ETFs hold IDEAYA Biosciences' stock?

ETFs with the largest weight of IDEAYA Biosciences (NASDAQ:IDYA) stock in their portfolio include Jacob Forward ETF (JFWD), Invesco Dorsey Wright Healthcare Momentum ETF (PTH) and ALPS Medical Breakthroughs ETF (SBIO).iShares Micro-Cap ETF (IWC).

What other stocks do shareholders of IDEAYA Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEAYA Biosciences investors own include Aldeyra Therapeutics (ALDX), Fulcrum Therapeutics (FULC), OPKO Health (OPK), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Boeing (BA), Xeris Biopharma (XERS), Entasis Therapeutics (ETTX), Livongo Health (LVGO) and NVIDIA (NVDA).

When did IDEAYA Biosciences IPO?

(IDYA) raised $70 million in an initial public offering (IPO) on Thursday, May 23rd 2019. The company issued 5,000,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, Citigroup and Jefferies acted as the underwriters for the IPO.

Who are IDEAYA Biosciences' major shareholders?

IDEAYA Biosciences' stock is owned by a number of retail and institutional investors. Top institutional investors include Federated Hermes Inc. (6.03%), Price T Rowe Associates Inc. MD (5.53%), Price T Rowe Associates Inc. MD (5.53%), Vanguard Group Inc. (5.39%), Capital Research Global Investors (3.07%) and BVF Inc. IL (2.68%). Insiders that own company stock include Briseno Andres Ruiz, Jason Throne, Michael P Dillon, Michael P Dillon, Paul A Stone and Yujiro S Hata.
View institutional ownership trends
.

How do I buy shares of IDEAYA Biosciences?

Shares of IDYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IDYA) was last updated on 2/26/2024 by MarketBeat.com Staff